Induction of tumor immunity by variants of folate binding protein
AssigneesBoard of Regents, The University of Texas System, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
InventorsConstantin G. Ioannides, George E. Peoples, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by energy, as in unresponsiveness.
Claims2
A peptide comprising the amino acid sequence of a variant of a peptide fragment of the polypeptide of SEQ ID NO:10, wherein said peptide is of at least 10 amino acids or up to about 30 amino acids, comprises SEQ ID NO:268 but for substitution therein of the amino acids at positions 1 and 7 thereof by phenylalanine and threonine, respectively, and further comprises from 1 to 21 additional contiguous amino acids of the amino acid sequences of SEQ ID NO:10 that flank SEQ ID NO:268 as contained therein.
Dependencies are inferred from the claim text.